Bottom line
IBB vs FBT: the short answer
IBB (iShares Biotechnology ETF) and FBT (First Trust NYSE Arca Biotechnology Index Fund) are quite different portfolios: only about 30% of their top holdings (by weight) are shared.
But IBB is far broader, holding 254 positions to 32 for FBT, so beyond the top names it adds exposure FBT doesn't have.
IBB is cheaper at 0.44% vs 0.55% — a difference of $11 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs +2.5% for IBB.
Updated Nov 19, 2026
IBB vs FBT side by side
| IBB | FBT | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | First Trust |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.55% |
| Annual cost per $10k | $44 | $55 |
| 10-yr cost on $10k (prospectus) | $555 | — |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +28.0% | +24.1% |
| 5-yr return (annualized) | +2.5% | +4.3% |
| 10-yr return (annualized) | +4.4% | +6.3% |
| Best quarter | +26.8% | +27.8% |
| Worst quarter | −22.9% | −22.5% |
| Net assets (fund) | $5.9B | $2.8B |
| Number of holdings | 254 | 32 |
| Portfolio turnover | 27% | 37% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | FBT | Difference |
|---|---|---|---|
| 2025 | +28.0% | +24.1% | +3.9% |
| 2024 | −2.4% | +5.8% | −8.2% |
| 2023 | +3.6% | +2.3% | +1.4% |
| 2022 | −13.6% | −4.6% | −9.0% |
| 2021 | +1.0% | −3.6% | +4.6% |
| 2020 | +25.9% | +12.9% | +13.0% |
| 2019 | +24.8% | +19.8% | +5.0% |
| 2018 | −9.1% | −0.2% | −8.9% |
| 2017 | +21.2% | +37.0% | −15.8% |
| 2016 | −21.5% | −19.6% | −1.9% |
Source: Fund prospectus bar charts
Holdings overlap
13 of IBB's top 25 holdings also appear in FBT's top 25.
| Holding | IBB | FBT |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 3.07% |
| Amgen, Inc. | 7.50% | 2.78% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 2.52% |
| Argenx SE | 3.15% | 3.13% |
| Natera, Inc. | 2.11% | 3.79% |
| Biogen, Inc. | 2.03% | 3.37% |
| United Therapeutics Corp. | 1.82% | 2.56% |
| Incyte Corp. | 1.62% | 3.18% |
| Illumina, Inc. | 1.41% | 3.92% |
| Genmab A/S | 1.38% | 2.62% |
| Neurocrine Biosciences, Inc. | 1.34% | 3.53% |
| Exelixis, Inc. | 1.07% | 3.32% |
| BioMarin Pharmaceutical, Inc. | 1.02% | 2.83% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
FAQ
What is the difference between IBB and FBT?
Which is cheaper, IBB or FBT?
Should I own both IBB and FBT?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.